Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 10Gynecologic 7Gastrointestinal 6Thoracic 5Other hematologic neoplasm 3Head & Neck 3CNS 3Genitourinary 2Sarcoma 1Myeloid 1Lymphoid 1Dermatologic 1Classical hematology 1

Conditions

Prostatic Neoplasms 1641Carcinoma, Renal Cell 504Urinary Bladder Neoplasms 462Carcinoma, Transitional Cell 234Breast Neoplasms 228Kidney Neoplasms 217Neoplasms 194Carcinoma, Non-Small-Cell Lung 173Colorectal Neoplasms 172Ovarian Neoplasms 163Melanoma 162Neoplasm Metastasis 143Lung Neoplasms 128Non-Muscle Invasive Bladder Neoplasms 107Pancreatic Neoplasms 103Stomach Neoplasms 101Uterine Cervical Neoplasms 93Squamous Cell Carcinoma of Head and Neck 86Endometrial Neoplasms 84Carcinoma, Hepatocellular 77Sarcoma 75Esophageal Neoplasms 72Head and Neck Neoplasms 70Triple Negative Breast Neoplasms 67Adenocarcinoma 66Colonic Neoplasms 53Testicular Neoplasms 52Disease 47Urologic Neoplasms 46Wilms Tumor 45

Interventions

Carboplatin 2olaparib 1liposomal doxorubicin 1Taxes 1Paclitaxel 1Lomustine 1Irinotecan 1Gemcitabine 1Doxorubicin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × Genitourinary × 1 year × Clear all
NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT04038502 2025-08-20

COBRA

VA Office of Research and Development

Phase 2 Recruiting
100 enrolled
Classical hematologyGenitourinary

Fanconi Anemia, Complementation Group N, Fanconi Anemia, Complementation Group D1, Hereditary Sensory and Autonomic Neuropathies, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡